ThrombinIts Key Role in Thrombogenesis-Implications for Its Inhibition: 1st Edition (Hardback) book cover

ThrombinIts Key Role in Thrombogenesis-Implications for Its Inhibition

1st Edition

By Michael R. Buchanan, Frederick A. Ofosu, Stephanie J. Brister

CRC Press

230 pages

Purchasing Options:$ = USD
Hardback: 9780849376498
pub: 1994-10-03
SAVE ~$64.50
Currently out of stock
$430.00
$365.50
x

FREE Standard Shipping!

Description

This new multi-authored book reviews the current understanding of the role of thrombin in venous and arterial thrombosis and its inhibition in the clinical setting. Heparin, the most widely used antithrombotic, does not effectively regulate thrombin or its formation. Accumulating evidence suggests that other antithrombins are effective in some of the situations where heparin is not. Discussions include the current knowledge on antithrombotic prophylaxis and therapy, from the perspective of the role in thrombin in venous and arterial vascular disease, the limitations of the current anticoagulant therapies, and potential and limitations of newer antithrombins currently being tested in several experimental and clinical settings. Thrombin helps the clinician to better rationalize the use of specific antithrombins in the prevention and management of thrombotic disease and provides the basic scientist with a better understanding of the goals the clinician attempts to achieve with antithrombotic therapy.

Table of Contents

Thrombin-Catalyzed Amplification and Inhibitory Reactions of Blood Coagulation, F.A. Ofosu, M.R. Buchanan, and S.J. Brister

Introduction

Acceleration of Blood Coagulation

Summary

The Structural Basis for Thrombin Inhibition by Hirudin and Serpins, M.T. Stubbs and W. Bode

Introduction

Thrombin Structure and Its Sites of Interaction

Interaction with Fibrinogen

Interaction with Hirudin

Interaction with Serpins

Summary

Development and Rationale for the Use of Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thrombosis, J.R. Leclerc

Introduction

Unfractionated Heparin

Low Molecular Weight Heparins

Mechanism of Action

Advantages of Low Molecular Weight Heparin

Clinical Studies

Heparin Cofactor II and the Prevention and Treatment of Thrombosis, M.R. Buchanan, S.J. Brister, and F.A. Ofosu

Introduction

Why Target Thrombin for Inhibition?

The Basis for Antithrombotic Therapy

Inhibition of Surface-Bound Thrombin

Thrombin HCII Inhibition

Inhibition of Thrombin by Heparin Cofactor II: Effect on Thrombus Formation/Growth in the Experimental Setting

Conclusion

Future Directions

Development and Rationale for the Use of Direct Thrombin Inhibitors in the Prevention and Treatment of Arterial and Venous Thrombosis, J.S. Ginsberg

Introduction

Clinical Studies of Direct Thrombin Inhibitors

Development and Rationale for Use of Anti-Thrombins in Arterial Thrombosis, S.J. Brister, F.A. Ofosu, and M.R. Buchanan

Introduction

The Prothrombotic State

Regulation of the Prothrombotic State

Conclusion

Pediatric Thromboembolism: Epidemiology, Prevention and Treatment, M. Andrew and M. David

Introduction

The Relationship Between Age and the Occurrence of DVT/PE

Mechanisms Protecting Children from Thromboembolic Complications

The Epidemiology of DVT/PE in Children

Clinical Outcome

Conclusion

The Role of Thrombin Inhibition in Thrombolytic Therapy, M. Prins, B. Girolami, and E. Bernardi

Introduction

Thrombin Function in Thrombolysis

Thrombin Inhibition in Thrombolysis

Conclusion

Outstanding Issues

Thrombosis and Pregnancy, J.S. Ginsberg and P. Brill-Edwards

Introduction

Hypercoagulability as a Consequence of Pregnancy

Epidemiology of Venous Thrombosis During Pregnancy

Diagnosis of DVT/PE During Pregnancy

Diagnosis of DVT

Diagnostic Tests for DVT

Diagnostic Tests for PE

Treatment of DCT/PE During Pregnancy

Inherited Molecular Deficiencies

The Hypercoagulable State in Cancer: Increased Thrombin Generation and Impaired Thrombin Inhibition, A. Falanga, S. Cortelazzo, and T. Barbul

Introduction

Prevalence of Hemostatic Disorders in Cancer

Abnormalities of Clotting Tests in Cancer

Therapy

Index

Subject Categories

BISAC Subject Codes/Headings:
MED038000
MEDICAL / Hematology